Literature DB >> 15703832

Mucinous carcinomas of the colorectum have distinct molecular genetic characteristics.

Geun Am Song1, Guoren Deng, Ian Bell, Sanjay Kakar, Marvin H Sleisenger, Young S Kim.   

Abstract

We compared the frequency of CpG island methylation phenotype (CIMP), inactivation of APC, p53 and DCC genes and K-ras and BRAF mutations in 39 mucinous carcinomas (MC) and 34 non-mucinous carcinomas (NMC) of the colorectum with different microsatellite instability (MSI) status. The higher incidence of MSI (36% vs. 18%) was observed in MC compared with NMC. APC inactivation and K-ras mutations occurred more frequently in NMC (APC, 88%, p<0.001; K-ras, 58%, p=0.01) than in MC (APC, 24%; K-ras, 28%) regardless of MSI status. BRAF mutation occurred at a higher frequency in MC (18%, p=0.01) than in NMC (0%). However, with respect to inactivation of p53 and DCC, MSI status did matter and in both NMC and MC, more frequent inactivation of p53 and DCC was observed in MSS tumors than in MSI tumors. MSS tumors of NMC had a higher frequency of p53 (58% by IHC, p=0.03 and 83% by LOH, p=0.02) and DCC inactivation (83%, p=0.02) compared to MSI tumors of NMC (p53, 33% by IHC and 20% by LOH; DCC, 20%). MSS tumors of MC also showed a higher frequency of p53 and DCC inactivation (p53, 45% by IHC, p=0.02 and 53% by LOH, p=0.005; DCC, 82%, p=0.001) compared to MSI tumors of MC (p53, 0% by IHC and 0% for LOH; DCC, 17%). MC showed a higher frequency of CIMP compared with NMC (41% vs. 11%, p=0.01). These results indicate that mucinous carcinomas of the colorectum exhibit distinct molecular genetic characteristics and may arise from distinct pathogenic pathways.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15703832

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  20 in total

1.  Mapping clinicopathological entities within colorectal mucinous adenocarcinomas: a hierarchical clustering approach.

Authors:  Charly Liddell; Laure Droy-Dupré; Sylvie Métairie; Fabrice Airaud; Christelle Volteau; Stéphane Bezieau; Christian L Laboisse; Jean-François Mosnier
Journal:  Mod Pathol       Date:  2017-04-21       Impact factor: 7.842

2.  Epigenetic changes (aberrant DNA methylation) in colorectal neoplasia.

Authors:  Young S Kim; Guoren Deng
Journal:  Gut Liver       Date:  2007-06-30       Impact factor: 4.519

3.  Fluorescent conjugated polymer-based FRET technique for detection of DNA methylation of cancer cells.

Authors:  Fude Feng; Libing Liu; Shu Wang
Journal:  Nat Protoc       Date:  2010-06-10       Impact factor: 13.491

4.  Prognostic implications of mucinous histology in stage III colon cancer with the receipt of adjuvant chemotherapy.

Authors:  Feng Yu; Luqiao Huang; Feng Shen; Shuang Wu; Jian Chen
Journal:  J Gastrointest Oncol       Date:  2020-10

5.  Clinicopathological features and survival outcomes of primary signet ring cell and mucinous adenocarcinoma of colon: retrospective analysis of VACCR database.

Authors:  Ramya Thota; Xiang Fang; Shanmuga Subbiah
Journal:  J Gastrointest Oncol       Date:  2014-02

6.  Association Between Prognosis and Tumor Laterality in Early-Stage Colon Cancer.

Authors:  Safiya Karim; Kelly Brennan; Sulaiman Nanji; Scott R Berry; Christopher M Booth
Journal:  JAMA Oncol       Date:  2017-10-01       Impact factor: 31.777

7.  Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy.

Authors:  D-W Lee; S-W Han; H J Lee; Y-Y Rhee; J M Bae; N-Y Cho; K-H Lee; T-Y Kim; D-Y Oh; S-A Im; Y-J Bang; S-Y Jeong; K J Park; J-G Park; G H Kang; T-Y Kim
Journal:  Br J Cancer       Date:  2013-05-07       Impact factor: 7.640

8.  The clinicopathological features of colorectal mucinous adenocarcinoma and a therapeutic strategy for the disease.

Authors:  Masakatsu Numata; Manabu Shiozawa; Takuo Watanabe; Hiroshi Tamagawa; Naoto Yamamoto; Soichiro Morinaga; Kazuteru Watanabe; Teni Godai; Takashi Oshima; Shoichi Fujii; Chikara Kunisaki; Yasushi Rino; Munetaka Masuda; Makoto Akaike
Journal:  World J Surg Oncol       Date:  2012-06-15       Impact factor: 2.754

9.  A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases.

Authors:  Nicola S Meagher; Linyuan Wang; Peter F Rambau; Maria P Intermaggio; David G Huntsman; Lynne R Wilkens; Mona A El-Bahrawy; Roberta B Ness; Kunle Odunsi; Helen Steed; Esther Herpel; Michael S Anglesio; Bonnie Zhang; Neil Lambie; Anthony J Swerdlow; Jan Lubiński; Robert A Vierkant; Ellen L Goode; Usha Menon; Aleksandra Toloczko-Grabarek; Oleg Oszurek; Sanela Bilic; Aline Talhouk; Montserrat García-Closas; Qin Wang; Adeline Tan; Rhonda Farrell; Catherine J Kennedy; Mercedes Jimenez-Linan; Karin Sundfeldt; John L Etter; Janusz Menkiszak; Marc T Goodman; Paul Klonowski; Yee Leung; Stacey J Winham; Kirsten B Moysich; Sabine Behrens; Tomasz Kluz; Robert P Edwards; Jacek Gronwald; Francesmary Modugno; Brenda Y Hernandez; Christine Chow; Linda E Kelemen; Gary L Keeney; Michael E Carney; Yanina Natanzon; Gregory Robertson; Raghwa Sharma; Simon A Gayther; Jennifer Alsop; Hugh Luk; Chloe Karpinskyj; Ian Campbell; Peter Sinn; Aleksandra Gentry-Maharaj; Penny Coulson; Jenny Chang-Claude; Mitul Shah; Martin Widschwendter; Katrina Tang; Minouk J Schoemaker; Jennifer M Koziak; Linda S Cook; James D Brenton; Frances Daley; Björg Kristjansdottir; Constantina Mateoiu; Melissa C Larson; Paul R Harnett; Audrey Jung; Anna deFazio; Kylie L Gorringe; Paul D P Pharoah; Parham Minoo; Colin Stewart; Oliver F Bathe; Xianyong Gui; Paul Cohen; Susan J Ramus; Martin Köbel
Journal:  Mod Pathol       Date:  2019-06-25       Impact factor: 8.209

10.  Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy.

Authors:  V Catalano; F Loupakis; F Graziano; U Torresi; R Bisonni; D Mari; L Fornaro; A M Baldelli; P Giordani; D Rossi; P Alessandroni; L Giustini; R R Silva; A Falcone; S D'Emidio; S L Fedeli
Journal:  Br J Cancer       Date:  2009-03-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.